Neuronetics announced two publications highlighting the effectiveness of TMS for depression and the superiority of the PHQ-9 assessment tool.
Quiver AI Summary
Neuronetics, Inc. announced the publication of two peer-reviewed studies in the Transcranial Magnetic Stimulation journal, highlighting the effectiveness of transcranial magnetic stimulation (TMS) for treating depression. The first study shows that TMS leads to universal improvement in depressive symptoms across a broad range, challenging the idea of targeting specific symptoms with tailored TMS protocols. The second study indicates that the Patient Health Questionnaire-9 (PHQ-9) is more sensitive than the Quick Inventory of Depressive Symptomatology (QIDS-SR) in assessing TMS outcomes, reflecting higher remission rates and better capture of symptom improvement. Keith J. Sullivan, CEO of Neuronetics, emphasized the importance of these findings in enhancing mental health treatment. Neuronetics continues to lead in advancing TMS therapies and improving patient care through evidence-based insights.
Potential Positives
- Neuronetics published two peer-reviewed studies in the inaugural edition of the Transcranial Magnetic Stimulation journal, reinforcing its leadership in TMS therapy.
- The studies provide compelling evidence that TMS significantly improves depressive symptoms, supporting its clinical efficacy.
- The findings suggest that the PHQ-9 is a more effective measurement tool for assessing TMS outcomes compared to the QIDS-SR, offering clinicians better insights for treatment evaluation.
- Neuronetics continues to demonstrate commitment to advancing mental health treatment through robust research and evidence-based practices, enhancing its reputation in the healthcare industry.
Potential Negatives
- The press release does not provide detailed data or specific results from the studies, which may undermine the credibility of the claims made about TMS's effectiveness.
- While it highlights TMS’s broad antidepressant effects, it challenges established theories on TMS treatment protocols, which could generate skepticism or criticism from the scientific community.
- The mention of the comparison between PHQ-9 and QIDS-SR raises concerns about the reliability of the latter tool, potentially impacting its use in clinical settings and the company’s standing within the mental health community.
FAQ
What are the key findings of the recent TMS publications?
The publications reveal that TMS broadly improves depressive symptoms and highlight the superior sensitivity of the PHQ-9 assessment tool.
How does TMS therapy impact depressive symptoms?
TMS therapy induces universal improvement across varying depressive symptoms rather than targeting specific issues, providing comprehensive treatment.
What tools were compared for measuring TMS outcomes?
The study compared the Patient Health Questionnaire-9 (PHQ-9) and the Quick Inventory of Depressive Symptomatology (QIDS-SR) for effectiveness in measuring outcomes.
Why is the PHQ-9 preferred over the QIDS-SR?
The PHQ-9 shows greater sensitivity to changes in depressive symptoms and higher remission rates compared to the QIDS-SR.
What is NeuroStar Advanced Therapy?
NeuroStar Advanced Therapy is a non-invasive TMS treatment designed to improve the quality of life for patients with depression.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STIM Insider Trading Activity
$STIM insiders have traded $STIM stock on the open market 12 times in the past 6 months. Of those trades, 10 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $STIM stock by insiders over the last 6 months:
- ROBERT CASCELLA has made 5 purchases buying 209,000 shares for an estimated $175,110 and 0 sales.
- GLENN P MUIR has made 5 purchases buying 100,171 shares for an estimated $85,128 and 0 sales.
- WILLIAM ANDREW MACAN (EVP, GC, CCO and CS) sold 1,541 shares for an estimated $1,263
- STEPHEN FURLONG (EVP, CFO and Treasurer) sold 1,368 shares for an estimated $1,121
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STIM Hedge Fund Activity
We have seen 14 institutional investors add shares of $STIM stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARCHON CAPITAL MANAGEMENT LLC removed 2,473,269 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,879,189
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 2,387,418 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,813,960
- FIRST WASHINGTON CORP removed 1,274,540 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $968,395
- MASTERS CAPITAL MANAGEMENT LLC added 1,200,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $911,760
- CANNELL CAPITAL LLC removed 1,067,037 shares (-44.8%) from their portfolio in Q3 2024, for an estimated $810,734
- FIRST EAGLE INVESTMENT MANAGEMENT, LLC removed 1,039,009 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $789,439
- G2 INVESTMENT PARTNERS MANAGEMENT LLC removed 681,461 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $517,774
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MALVERN, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two peer-reviewed publications in the inaugural edition of the
Transcranial Magnetic Stimulation
journal. The first provides compelling evidence that transcranial magnetic stimulation (TMS) induces universal improvement in depressive symptoms. The second paper demonstrates the superior sensitivity of one widely used depression assessment (the Patient Health Questionnaire-9, or PHQ-9) over another (the Quick Inventory of Depressive Symptomatology: Self-Report, or QIDS-SR) for measuring TMS outcomes.
“NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and CEO of Neuronetics. “These findings not only reinforce TMS’s powerful ability to improve many symptoms people with depression face, but also provide clinicians with insights on common tools so they can deliver more precise and effective care. These publications further cement NeuroStar’s position as the leader in advancing TMS therapy and shaping the future of depression treatment.”
The following publications highlight key findings about the impact and assessment of TMS therapy:
The Profile of Symptom Change with Transcranial Magnetic Stimulation for Major Depressive Disorder
About the publication:
This analysis explores how TMS influences individual depressive symptoms in a cohort of 578 patients diagnosed with major depressive disorder (MDD). Researchers utilized two validated assessment tools—the PHQ-9 and the QIDS-SR—to evaluate the severity of depressive symptoms, including mood, energy, appetite, self-view, and sleep disturbances, before and after at least 36 TMS treatments. The study also examined three distinct TMS protocols to compare their effectiveness.
Results:
The data revealed that TMS has a broad antidepressant effect, improving all depressive symptoms with similar magnitude rather than targeting specific symptoms. This challenges a theory in the scientific community that TMS coil positioning should be modified according to the specific depressive symptoms being targeted. Rather, standard clinical TMS appears to function as a comprehensive treatment option for a wide range of depressive symptom profiles. Furthermore, the study found that all three TMS protocols studied were equally effective, giving clinicians greater flexibility in treatment delivery while maintaining consistent results.
Comparison of the PHQ-9 and the QIDS-SR in Assessing the Antidepressant Effects of Transcranial Magnetic Stimulation: Sensitivity to Change
About the publication:
This evaluation compared the sensitivity and reliability of two commonly used depression assessment tools—the PHQ-9 and the QIDS-SR—in capturing symptom improvements following TMS treatment. Data from 578 patients were retrospectively analyzed to evaluate how well each tool reflected changes in depressive symptom severity.
Results:
The PHQ-9 demonstrated superior sensitivity to symptom improvement and identified higher remission rates than the QIDS-SR. Additionally, the PHQ-9 showed stronger reliability in measuring depression severity as a single factor. In contrast, the QIDS-SR was less sensitive, often underreporting symptoms prior to treatment and improvements following treatment; it also categorized more patients as “non-responders.” These findings suggest that the PHQ-9 is a more sensitive measure of TMS-induced changes in depressive symptoms.
“The two publications provide clinicians with valuable insights regarding how best to measure the benefits of TMS and its impact on patients’ symptoms. The first paper demonstrates the effects of TMS are generalized, meaning all depressive symptoms improve relatively equally; this implies that TMS has a widespread impact across different parts of the brain responsible for depressive symptoms,” said Dr. Harold A. Sackeim, Professor, Department of Psychiatry, Medical University of South Carolina. “The second paper shows the PHQ-9 is a superior scale to measure patient progress than the QIDS-SR, which will impact how the clinical field uses these common measurement tools.”
By providing robust evidence of TMS’s effectiveness and actionable insights for clinicians, Neuronetics continues to lead the charge in transforming depression treatment. For more information about NeuroStar Advanced Therapy, please visit
www.neurostar.com
.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 6.9 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO
®
(esketamine) CIII Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.
1
Greenbrook has provided more than 1.68 million treatments to over 51,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit
NeuroStar.com
.
1
The effectiveness of SPRAVATO
®
in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO
®
does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO
®
. For more important safety information about SPRAVATO
®
, please visit spravatohcp.com.
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
